Your browser doesn't support javascript.
loading
Shedding light on the hidden human proteome expands immunopeptidome in cancer.
Li, Yongsheng; Zhang, Yunpeng; Pan, Tao; Zhou, Ping; Zhou, Weiwei; Gao, Yueying; Zheng, Shaojiang; Xu, Juan.
Affiliation
  • Li Y; College of Biomedical Information and Engineering, Hainan Women and Children's Medical Center, Hainan Medical University, Haikou 571199, China.
  • Zhang Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
  • Pan T; College of Biomedical Information and Engineering, Hainan Women and Children's Medical Center, Hainan Medical University, Haikou 571199, China.
  • Zhou P; Department of Radiotherapy, the First Affiliated Hospital of Hainan Medical University, Hainan, China.
  • Zhou W; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
  • Gao Y; College of Biomedical Information and Engineering, Hainan Women and Children's Medical Center, Hainan Medical University, Haikou 571199, China.
  • Zheng S; Key Laboratory of Emergency and Trauma of Ministry of Education, Tumor Institute of the First Affiliated Hospital, Hainan Medical University, Haikou, 571199, China.
  • Xu J; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Brief Bioinform ; 23(2)2022 03 10.
Article in En | MEDLINE | ID: mdl-35189633
ABSTRACT
Unrestrained cellular growth and immune escape of a tumor are associated with the incidental errors of the genome and transcriptome. Advances in next-generation sequencing have identified thousands of genomic and transcriptomic aberrations that generate variant peptides that assemble the hidden proteome, further expanding the immunopeptidome. Emerging next-generation sequencing technologies and a number of computational methods estimated the abundance of immune infiltration from bulk transcriptome have advanced our understanding of tumor microenvironments. Here, we will characterize several major types of tumor-specific antigens arising from single-nucleotide variants, insertions and deletions, gene fusion, alternative splicing, RNA editing and non-coding RNAs. Finally, we summarize the current state-of-the-art computational and experimental approaches or resources and provide an integrative pipeline for the identification of candidate tumor antigens. Together, the systematic investigation of the hidden proteome in cancer will help facilitate the development of effective and durable immunotherapy targets for cancer.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Proteome / Neoplasms Limits: Humans Language: En Year: 2022 Type: Article

Full text: 1 Database: MEDLINE Main subject: Proteome / Neoplasms Limits: Humans Language: En Year: 2022 Type: Article